Skip to main content
TASCOM Co.,Ltd. logo

TASCOM Co.,Ltd. — Investor Relations & Filings

Ticker · 336040 ISIN · KR7336040001 KO Manufacturing
Open in API
Filings indexed 189 across all filing types
Latest filing 2021-07-27 AGM Information
Country KR South Korea
Listing KO 336040

About TASCOM Co.,Ltd.

http://tascom.org/

TASCOM Co., Ltd. is a company that develops, manufactures, and distributes medical devices, specializing in in vitro diagnostics (IVD) and diabetes management. Its key product is the SimplexTAS series, a point-of-care testing (POCT) immunochemistry system that functions as a portable analyzer for quantitative, multi-parameter biochemical immunoassays using small blood or urine samples. The company's portfolio also includes a range of diabetic supplies, such as blood glucose measurement systems and insulin syringes. Additionally, TASCOM is engaged in the research and development of cell therapy products.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice regarding the convocation of an Extraordinary General Meeting (EGM) for 'IdoBio'. It details the meeting date, location, agenda items (such as merger approval and articles of incorporation changes), and includes a correction notice for the schedule. This type of document is a standard proxy solicitation or notice of meeting material sent to shareholders to inform them of upcoming voting matters.
2021-07-27 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a corporate merger (회사합병 결정) between Yido Bio and Tascom. It details the merger schedule, valuation methods, and shareholder rights (such as appraisal rights). This type of filing is a formal regulatory announcement concerning M&A activity, which falls under the 'M&A Activity' category.
2021-07-26 Korean
[기재정정]증권신고서(합병)
M&A Activity Classification · 1% confidence The document is a '증권신고서(합병)' (Securities Registration Statement for Merger) which is a formal regulatory filing in South Korea. It details the merger between '주식회사 이도바이오' and '주식회사 타스컴', including the calculation of merger ratios, asset valuations, and legal justifications. This document is a primary regulatory filing related to M&A activity, not an announcement of a report (RPA). Therefore, it is classified as M&A Activity.
2021-07-26 Korean
[기재정정]증권신고서(합병)
M&A Activity Classification · 1% confidence The document is a 'Securities Registration Statement (Merger)' (증권신고서(합병)) which is a formal regulatory filing required for corporate mergers in South Korea. It contains detailed information about the merger ratio, valuation of the companies involved, and risk factors. It is a 'Correction Report' (정정신고) updating a previously submitted filing. This falls under the category of regulatory filings related to M&A activity.
2021-07-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (specifically a sale of 1,000 shares) by an executive (Um Bo-youl) of the company 'Idobio'. This type of filing is a standard disclosure for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2021-07-09 Korean
[첨부추가]증권신고서(합병)
M&A Activity Classification · 1% confidence The document is a '증권신고서(합병)' (Securities Registration Statement for Merger) filed with the Financial Services Commission (FSC) in South Korea. It details the terms of a merger between Yido Bio and Tascom, including merger ratios, financial risks, and key schedules. This type of document is a formal regulatory filing related to M&A activity.
2021-07-06 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.